Ablation for AF 'safe and effective' for women
The largest randomised controlled trial to date shows being female does not put patients at greater risk of complications
A patient’s sex should not influence the choice of whether or not to treat atrial fibrillation (AF) with ablation, researchers say in the wake of new data.
Concerns that women having ablation were at more risk of adverse events than men should be allayed by the findings of a post hoc analysis showing no difference in risk between the sexes, they said.
The US team used data from the CABANA trial, in which more than 2200 patients aged over 65 with AF were randomised to either
